|
1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV26–28 June 1999 - San Diego, CA, USA |
LIPODYSTROPHY AND METABOLIC CHANGES IN HIV-INFECTED PATIENTS TREATED WITH OR WITHOUT PIs
Antiviral Therapy 1999; 4(Suppl. 2):60(abstract no. 48)
F Boufassa1, A Dulioust2, C Gouiard1, AS Lascaux3, M Fénéant-Thibault1 and the LipoSud Study Committee
1Hôpital Bicêtre; 2Hôpital Béclère;and 3Hôpital Mondor, Assistance Publique-Hôpitaux de Paris,France
BACKGROUND AND OBJECTIVES: To describe the clinical and metabolic features of HIV-infected patients treated with PIs compared to those who received antiretroviral regimen without PI.
DESIGN: Preliminary analysis of the first 236 of 500 anticipated participants in an ongoing cross-sectional study of outpatients, which began in March 1999.
RESULTS: Demographic data, familial and personal vascular risk factors, history and duration of antiretroviral treatment, HIV viral load and CD4 cell count were collected and analysed according to clinical fat redistribution abnormalities and fasting metabolic disorders (serum cholesterol, triglyceride, glucose). Clinical examination was based on an assessment of abdominal and breast girth, wasting of the limbs and skin changes noted by the clinician and/or reported by the patients. The mean age at inclusion in the study was 37 years; 37% were women, 63% men. Abnormal clinical findings were more frequent among patients created with PI. Glucose level did not differ by treatment regimen. Mean cholesterol level was significantly higher among patients treated with PI than among patients treated with other antiretroviral drugs (5.59 mM versus 4.68 mM; P<0.001), as was mean triglyceride level (1.95 mM versus 1.50 mM; P=0.01). The relationship between metabolic changes, anmunovirological status and previous and current therapy regimens will be analysed.
CONCLUSION: In this preliminary analysis, significant differences were found in fasting metabolic disorders among patients treated with PI compared to those who were not. The major objective of this study is to define factors influencing the occurrence of lipodystrophy and dyslipidaemia in a large population of HIV-infected patients.
990626
48
Copyright © 1999 - International Medical Press Ltd. Reproduction of this abstract (other than one copy for personal reference) must be cleared through the Medical Editor, International Medical Press, 36 St Mary-at-Hill, London EC3R 8DU, United Kingdom.